Design, synthesis, and biological evaluation of novel γ-carboline ketones as anticancer agents

Jing Chen1, Tao Liu, Rui Wu

  • 1College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053 Zhejiang, China.

Insights

Novel gamma-carboline ketones show potent anticancer activity. Compound 6f inhibits tubulin polymerization, arresting cancer cell division, offering a promising new therapeutic strategy.

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Cancer Biology

Background:

  • γ-carboline derivatives are recognized for their diverse biological activities.
  • Developing novel cytotoxic agents is crucial for effective cancer chemotherapy.

Purpose of the Study:

  • To design and synthesize new γ-carboline ketones.
  • To evaluate their in vitro cytotoxic activity against human cancer cell lines.
  • To investigate the mechanism of action of the most potent compounds.

Main Methods:

  • Synthesis of novel γ-carboline ketones.
  • In vitro cytotoxicity assays against six human cancer cell lines (A549, SGC, HCT116, MCF-7, K562, K562R).
  • Mechanism of action studies, including tubulin polymerization inhibition and cell cycle analysis.

Main Results:

  • Most synthesized compounds exhibited moderate to potent cytotoxic activities.
  • Seven compounds demonstrated superior activity against the K562R cell line compared to taxol.
  • The most potent compound, 6f, was identified as a tubulin polymerization inhibitor (IC50 = 4.3 μM) and induced G2/M cell cycle arrest.

Conclusions:

  • The novel γ-carboline ketones are promising anticancer agents.
  • Compound 6f represents a potential lead for developing new tubulin-targeting cancer therapies.
  • Further investigation into these compounds could yield novel chemotherapeutic drugs.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...